Details of the Drug

General Information of Drug (ID: DMTZC5G)

Drug Name

Bezlotoxumab

Synonyms

CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava

Indication

Disease Entry	ICD 11	Status	REF
C. difficile infection	1A04	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Peptoclostridium difficile

ATC Code

J06BC03: Bezlotoxumab

J06BC: Antibacterial monoclonal antibodies

J06B: IMMUNOGLOBULINS

J06: IMMUNE SERA AND IMMUNOGLOBULINS

J: ANTIINFECTIVES FOR SYSTEMIC USE

Drug Type

Monoclonal antibody

ADMET Property

Clearance: The clearance of drug is 0.317 L/day []
Half-life: The concentration or amount of drug in body reduced by one-half in 19 Days [2]
Vd: The volume of distribution (Vd) of drug is 7.33 L []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Clostridium difficile Toxin B (CD toxB)	TTQH65V	TOXB_CLODI	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds